Clinical Trials
86 trialsNCT03317392 2026-05-20
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04071223 2026-05-13
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04071236 2026-05-13
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT04090398 2026-05-13
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04597125 2026-05-11
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
Bayer
Phase 4 Active not recruiting
NCT05133440 2026-04-28
A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03361735 2026-04-09
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04109729 2026-03-02
Rad2Nivo
University of Utah
Phase 1 Active not recruiting
NCT03344211 2026-02-27
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
University of Southern California
Phase 2 Active not recruiting
NCT00699751 2026-02-23
ALSYMPCA
Bayer
Phase 3 Completed
NCT04489719 2026-02-17
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
University of Washington
Recruiting
NCT05924672 2026-01-14
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
University of California, San Francisco
Phase 2 Active not recruiting
NCT02141438 2025-10-16
REASSURE
Bayer
Completed
NCT03737370 2025-10-07
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Tufts Medical Center
Phase 1 Completed
NCT04521361 2025-09-19
A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones
Bayer
Phase 1 Completed
NCT02803437 2025-07-10
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
Bayer
Completed
NCT03304418 2025-04-30
RROPE
University of Utah
Phase 2 Completed
NCT03076203 2025-04-29
Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)
Thomas Jefferson University
Phase 1 Completed
NCT03903835 2025-04-09
ProBio
Karolinska Institutet
Phase 3 Recruiting
NCT03093428 2025-03-28
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02043678 2025-02-19
ERA 223
Bayer
Phase 3 Completed
NCT03002220 2024-12-11
EXCAAPE
MedSIR
Phase 2 Completed
NCT03996473 2024-10-10
Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases
Bayer
Phase 1 Terminated
NCT04232761 2024-07-17
RAPIT
Bayer
Completed
NCT04587427 2024-03-08
DIRECT
Bayer
Completed
NCT03315260 2024-02-08
Treatment Satisfaction With Ra-223 in Japan
Bayer
Completed
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT04256993 2024-01-16
PRECISE
Bayer
Completed
NCT02258451 2023-11-24
Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer
Bayer
Phase 2 Completed
NCT00337155 2023-11-02
BAY88-8223, Dose Finding Study in Patients With HRPC
Bayer
Phase 2 Completed
NCT04681144 2023-10-26
QOLRAD
Bayer
Completed
NCT05301062 2023-09-22
CREDIT
Bayer
Terminated
NCT05771896 2023-09-14
CARE
GenesisCare USA
Phase 3 Withdrawn
NCT00667199 2023-04-19
BAY88-8223, Does Response Study in HRPC Patients
Bayer
Phase 2 Completed
NCT04237584 2022-10-07
ESCALATE
MANA RBM
Phase 3 Terminated
NCT02346526 2022-09-29
A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT02582749 2022-07-11
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04281147 2022-06-23
REACTIVATE
Bayer
Completed
NCT03223597 2022-04-15
ROTOR
The Netherlands Cancer Institute
Completed
NCT04516161 2022-03-31
EPIX
Bayer
Completed
NCT02135484 2022-02-17
Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
M.D. Anderson Cancer Center
Phase NA Completed
NCT03896984 2021-12-29
PHENIX
Bayer
Completed
NCT02398526 2021-11-02
PARABO
Bayer
Completed
NCT02450812 2021-11-02
URANIS
Bayer
Completed
NCT02366130 2021-10-07
Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03062254 2021-09-21
Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Completed
NCT04995614 2021-08-09
Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223
Radboud University Medical Center
Completed
NCT02463799 2021-07-08
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02283749 2021-02-02
BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Brown University
Phase 2 Completed
NCT03458559 2020-11-17
RaRe
Amsterdam UMC, location VUmc
Phase 3 Unknown